Obesity, complexity, and the lab: What 2025 taught us, and what comes next The complexity of working with the patient population in obesity continues to challenge traditional trial design. hVIVO looks to the year ahead.

#Obesity #cardiometabolicdiseases #earlyphaseresearch #clinicaltrialdesign #clinicaldevelopment #clinicaltrialsponsors #weightloss #obesitydrivencomorbidities #GLP1receptoragonists #MASLD #patientrecruitment #Personalisedtrialdesign #obesitytrials #cardiometabolicsector
zurl.co/ErmB8